DLBS1033
ApprovedSmall molecule
DLBS1033 is one of 138 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Approved.
5
Indications
13
Total Trials
1
Active Trials
137
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
676 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1DLBS1033
DDexa Medica Group
Approved
Tanzeum
GSKPreclinical
Insulin 320
Novo NordiskPreclinical
Adenocard
AstellasPreclinical
Golytely
BayerPreclinical
Myrbetriq
AstellasPreclinical
Lantus
SanofiPreclinical
Lixisenatide
SanofiPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Xifaxan
SSalix
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Ischemic stroke4 trials
Show 1 more trial
The Benefit of Add On DLBS1033 for Ischemic Stroke Patient
Unknown status·—·Phase 2/3·NCT04425590·180 enrolled
Type 2 Diabetes Mellitus1 trial
4 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DLBS1033. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- DDexa Medica Group